Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
405 participants
OBSERVATIONAL
2017-01-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
NCT02560441
GDP in Frontline Chemotherapy for Patients With PTCL-NOS
NCT02404571
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
NCT05254899
Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study
NCT07270861
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
NCT02533700
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nodal PTCL
1. newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma \[ALCL\], anaplastic lymphoma kinase \[ALK\]-negative) between January 1, 2005 and Jun 30, 2016
2. initially treated with curative intent
3. Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with between January 1, 2004 and April 30, 2016
* initially treated with curative intent
* Patients with standard 18F-fluorodeoxyglucose (FDG) PET or PET-CT data at the time of diagnosis and at the end of primary treatment
Exclusion Criteria
* Patients with ALCL-ALK+
* Patients who do not have 18F-FDG PET or PET-CT data either at diagnosis or at the end of treatment available for review
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chonnam National University Hospital
OTHER
Kyungpook National University Hospital
OTHER
Keimyung University Dongsan Medical Center
OTHER
Korea University Anam Hospital
OTHER
Korea University Guro Hospital
OTHER
Dong-A University Hospital
OTHER
Pusan National University Hospital
OTHER
Yeungnam University Hospital
OTHER
Inje University
OTHER
Chungnam National University Hospital
OTHER
Samsung Medical Center
OTHER
Chonbuk National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ho-Young Yhim
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ho-Young Yhim
Role: PRINCIPAL_INVESTIGATOR
Chonbuk National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chonbuk Nationla University Hospital
Jeonju, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
nodal PTCL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.